Terrestrial Presents Data on Needle-Free Microarray Patch (MAP) for Codelivery of Amylin Analog and GLP-1 Therapy Without Coformulation 

NEW ORLEANS, La., June 8, 2026 —Terrestrial Bio, Inc., a biotech company transforming the delivery of next-generation therapies, is presenting new preclinical data at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans. Building on the company’s 2025 lead program findings focused on its semaglutide microarray patch, Terrestrial’s new research demonstrates the translatability of its proprietary Tacterra™ MAP platform to deliver next-generation obesity therapies that involve co-delivery of  an amylin analog and a GLP-1 receptor agonist (GLP-1 RA).

"Codelivery of amylin analogs with GLP-1 RAs is of interest due to their synergistic therapeutic benefits for Type 2 diabetes and obesity, but administering these active pharmaceutical ingredients together has traditionally required a complex and expensive dual-chambered injector due to instability when coformulated," said Rachel Sha, CEO of Terrestrial Bio. "We've built a single, shelf-stable microarray patch that codelivers both therapies without coformulation. Patients will be able to simply apply the patch, and receive their medication in a pain free and easy way.” 

Terrestrial used CagriSema, a combination of GLP-1 RA semaglutide and amylin RA cagrilintide , as a model to evaluate in vitro and in vivo performance. MAPs and injections were evaluated in Göttingen minipigs. Liquid preparations of drug substance were injected separately into subcutaneous tissue, while the Tacterra™ MAP platform delivered CagriSema via a single MAP administration to the skin. Key findings included:

• Tacterra™ MAPs co-delivering cagrilintide and semaglutide via a single patch achieve comparable bioavailability to SC injection in a minipig model, providing a patient-friendly alternative to dual-chamber autoinjectors for combination therapies. 

• Tacterra™ MAPs significantly improve stability of cagrilintide and semaglutide compared to liquid drug substance, supporting cold-chain free storage.

To request a copy of the poster Terrestrial presented at ADA, email contact@terrestrialbio.com.

About Terrestrial Bio, Inc.

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1.

Terrestrial's proprietary Tacterra™ microarray patch (MAP) and applicator platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes. Once applied, each patch delivers bioactive tips into the skin, which dissolve quickly into the body, rapidly releasing their therapeutic payload. Designed for self-administration, the temperature-stable Tacterra™ platform enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.

Terrestrial has generated strong clinical and in-vivo proof of concept across multiple molecules. For more information, visitwww.terrestrialbio.com.